Pectoralis and Serratus Muscle Blocks

Post Operative Pain Control Clinical Trial

Official title: Pectoralis and Serratus Muscle Blocks for Analgesia After Minimally Invasive Cardiac Procedures

Status Completed

Clinical Trial Summary

The overall research plan is PECS/SAP blocks with liposomal bupivacaine improve the Overall Benefit Analgesia Score averaged over the postoperative days 1, 2, and 3. A 20% reduction on geometric means (i.e., true ratio of geometric means of 0.80) in OBAS will be considered the minimal clinically important benefit.

Clinical Trial Description

The primary aim is to determine whether a PECS/SAP block, using a mixture of bupivacaine and liposomal bupivacaine, provides superior recovery compared to routine parenteral and enteral analgesia in patients recovering from MICS. The primary outcome will be the simple multi-dimensional quality assessment, Overall Benefit Analgesia Score (OBAS score).53 Our secondary aims are to: 1) compare cumulative postoperative opioid consumption (pain medications administered over one-day periods quantified as morphine equivalents and provided by the EMR for the day of surgery and postoperative days 1, 2, and 3; 2) evaluate respiratory mechanics (forced expiratory volume in first minute (FEV1), forced vital capacity (FVC) and peak flow) after extubation on the postoperative days 1, 2 and 3 while patients remain hospitalized; and, (3) evaluate the Quality-of-Recovery-15 score on the postoperative days 1, 2 and 3. ;

Related Conditions & MeSH terms

• Pain, Postoperative
• Post Operative Pain Control

• NCT number: NCT03743194
• Study type: Interventional
• Source: The Cleveland Clinic
• Status: Completed
• Phase: Phase 4
• Start date: December 14, 2021
• Completion date: March 14, 2022